"ISO3CD","X","Y","GeoArea_Code","GeoArea_Desc","GoalCode","GoalDesc","TargetCode","TargetDesc","IndicatorCode","IndicatorDesc","IndicatorTier","SeriesCode","SeriesDesc","SeriesRelease","ReportingType_Code","ReportingType_Desc","Units_Code","Units_Desc","Footnotes_2008","Footnotes_2009","Footnotes_2010","Footnotes_2011","Footnotes_2012","Footnotes_2013","Footnotes_2014","Footnotes_2015","Footnotes_2016","Nature_Code_2008","Nature_Code_2009","Nature_Code_2010","Nature_Code_2011","Nature_Code_2012","Nature_Code_2013","Nature_Code_2014","Nature_Code_2015","Nature_Code_2016","Source_2008","Source_2009","Source_2010","Source_2011","Source_2012","Source_2013","Source_2014","Source_2015","Source_2016","TimeDetail_2008","TimeDetail_2009","TimeDetail_2010","TimeDetail_2011","TimeDetail_2012","TimeDetail_2013","TimeDetail_2014","TimeDetail_2015","TimeDetail_2016","Value_2008","Value_2009","Value_2010","Value_2011","Value_2012","Value_2013","Value_2014","Value_2015","Value_2016","Latest_Year","Latest_Value"
"","","","1","World","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","4","7","11","15","19","26","32","37","42",2016.0,"42"
"BGR","25.23763153","42.75731323","100","Bulgaria","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","69","94","94","94","92","90","90",2016.0,"90"
"MMR","96.51752295","21.19332882","104","Myanmar","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","E","","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","","14",2016.0,"14"
"BDI","29.89080992","-3.366387428","108","Burundi","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","14","96","96","95","94","94",2016.0,"94"
"","","","11","Western Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","1","6","11","14","26","39","50",2016.0,"50"
"KHM","104.922836","12.71163737","116","Cambodia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","68","87",2016.0,"87"
"DZA","2.678164227","28.15940032","12","Algeria","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","E","","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","","61",2016.0,"61"
"CMR","12.7419827","5.692387031","120","Cameroon","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","23","84","88","87","85","84",2016.0,"84"
"CAN","-101.6575058","57.72360191","124","Canada","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","42","50","58","66","73","79","79","79","79",2016.0,"79"
"","","","13","Central America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","10","33","70","83","85","78","88","92","91",2016.0,"91"
"","","","135","Caucasus and Central Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","0","8","11","18","26","69",2016.0,"69"
"","","","14","Eastern Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","3","15","28","55","71","74","77",2016.0,"77"
"CAF","20.93559492","7.003720791","140","Central African Republic","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","8","47","23","47","47","47",2016.0,"47"
"","","","142","Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","3","3","3","4","9","11","16","20",2016.0,"20"
"","","","143","Central Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","0","9.22623","12.90227","14.30096","18.11746","64.66682",2016.0,"64.66682"
"","","","145","Western Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","1","38","38","48","52","55","57","58","59",2016.0,"59"
"","","","15","Northern Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","3","9","16","33","33","44",2016.0,"44"
"","","","150","Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","12","18","37","40","43","43","45","45","54",2016.0,"54"
"","","","151","Eastern Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","2","3","6","6","6","6","7","26",2016.0,"26"
"CHL","-71.23029019","-35.2652885","152","Chile","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","54","82","79","92","90","90",2016.0,"90"
"","","","154","Northern Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","10","18","82","87","88","89","90","90","91",2016.0,"91"
"","","","155","Western Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","25","40","77","77","84","85","85","85","85",2016.0,"85"
"","","","17","Middle Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","8","20","33","55","63","65",2016.0,"65"
"COL","-73.07446751","3.888209046","170","Colombia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","22","46","84","87","89","91","89",2016.0,"89"
"COG","15.22052612","-0.840544119","178","Congo","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","10","85","85","80","80",2016.0,"80"
"","","","18","Southern Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","8","49","52","61","61","66","76","72",2016.0,"72"
"COD","23.65496507","-2.877154732","180","Democratic Republic of the Congo","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","9","13","31","61","73","77",2016.0,"77"
"CRI","-84.19712782","9.970998683","188","Costa Rica","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","48","94","68","89","94","83","94","94",2016.0,"94"
"","","","19","Americas","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","28","34","51","69","77","79","83","85","84",2016.0,"84"
"CYP","33.22285964","35.05659437","196","Cyprus","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","81","81",2016.0,"81"
"","","","199","Least Developed Countries (LDCs)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","1","7","15","30","52","63","72",2016.0,"72"
"","","","2","Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","3","11","20","33","48","55","62",2016.0,"62"
"AND","1.576257417","42.54548611","20","Andorra","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","93","92","92",2016.0,"92"
"","","","202","Sub-Saharan Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","3","12","22","36","51","59","65",2016.0,"65"
"BEN","2.339933594","9.65401646","204","Benin","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","36","67","70","71","75","75",2016.0,"75"
"DNK","9.326571283","56.03829721","208","Denmark","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","86","88","90","93","90","93","91","94",2016.0,"94"
"","","","21","Northern America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","88.7891","89.37687","89.99677","91.56223","90.32885","90.85021","91.7608","91.76517","91.77348",2016.0,"91.77348"
"DOM","-70.49847576","18.89832088","214","Dominican Republic","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","27","22","30",2016.0,"30"
"ECU","-78.37005241","-1.447785891","218","Ecuador","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","17","71","94","90","86","81","84",2016.0,"84"
"SLV","-88.86862995","13.73603564","222","El Salvador","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","69","98","94","92","86","98","90",2016.0,"90"
"ETH","39.63505296","8.631223181","231","Ethiopia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","12","38","63","76","76","76",2016.0,"76"
"ERI","38.11074289","16.12894644","232","Eritrea","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","95","95",2016.0,"95"
"AGO","17.57817062","-12.33724746","24","Angola","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","9","45","58","58",2016.0,"58"
"FJI","177.9660884","-17.83301566","242","Fiji","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","87","99","99","99",2016.0,"99"
"FIN","23.308447","61.91586738","246","Finland","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","92","92","92","92","92","92","87",2016.0,"87"
"FRA","2.457288129","46.62660861","250","France","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","89","89","89","89","89","90","91",2016.0,"91"
"DJI","42.18274707","11.56004161","262","Djibouti","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","82","78","82","82",2016.0,"82"
"GEO","43.3713615","42.04813028","268","Georgia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","16","75",2016.0,"75"
"GMB","-15.39944785","13.45295927","270","Gambia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","99","95","98","96","96","97","95",2016.0,"95"
"PSE","35.25694122","31.94347933","275","State of Palestine","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","25","97","99","99","99",2016.0,"99"
"DEU","10.3806066","51.08862743","276","Germany","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","68","85","86","86","86","86","86","86","86",2016.0,"86"
"GHA","-1.205623522","7.964825185","288","Ghana","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","43","89","99","88","93",2016.0,"93"
"","","","29","Caribbean","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","0","2","3","12","11","13",2016.0,"13"
"KIR","-157.5643005","1.768837732","296","Kiribati","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","40","57","74","79",2016.0,"79"
"","","","30","Eastern Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","0","0","0","0","8","8",2016.0,"8"
"GRC","22.58307827","39.47301873","300","Greece","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","32","32","96","96","96",2016.0,"96"
"AZE","50.01064725","40.39229544","31","Azerbaijan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","64","94","97",2016.0,"97"
"ARG","-65.14563274","-35.19446255","32","Argentina","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","41","86","89","82","82",2016.0,"82"
"GTM","-91.2312746","15.00273719","320","Guatemala","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","24","51","82","81",2016.0,"81"
"GUY","-58.97322037","4.788012784","328","Guyana","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","50","90","96","97","94","92",2016.0,"92"
"","","","34","Southern Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","0","0","9","11","16","21",2016.0,"21"
"HND","-86.59974381","14.82243161","340","Honduras","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","97","97","97","97","97","97",2016.0,"97"
"HUN","19.41221519","47.1651448","348","Hungary","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","84","90","92","93","91","98",2016.0,"98"
"","","","35","South-Eastern Asia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","0","0","0","8","7","13",2016.0,"13"
"ISL","-19.02116966","64.79134763","352","Iceland","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","86","88","90","91","90",2016.0,"90"
"AUS","134.3499412","-25.57717202","36","Australia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","91","91","91","91","91","91","91","93","94",2016.0,"94"
"IRL","-7.121425272","53.25274054","372","Ireland","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","43","90","91","91","92","92","91",2016.0,"91"
"ISR","34.62277992","31.06164552","376","Israel","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","92","93","94","94","94","93",2016.0,"93"
"ITA","12.57022427","42.79917282","380","Italy","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","60","66","71","76","82","87","87","89","89",2016.0,"89"
"CIV","-5.552690016","7.62211586","384","Cte d'Ivoire","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","2","72","83",2016.0,"83"
"","","","39","Southern Europe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","22","24","26","30","35","37","41","43","43",2016.0,"43"
"JPN","139.2716103","36.6554539","392","Japan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","96","99",2016.0,"99"
"KAZ","66.65359159","48.01963494","398","Kazakhstan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","37","52","58","74","97",2016.0,"97"
"AFG","66.02688198","33.83160199","4","Afghanistan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","40","65","65",2016.0,"65"
"KEN","37.86096816","0.534797278","404","Kenya","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","85","82","75","81","75","78",2016.0,"78"
"KOR","127.8610254","36.45201023","410","Republic of Korea","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","97","98",2016.0,"98"
"KWT","47.49305029","29.53949468","414","Kuwait","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","99","99","98","99","99","99","94","99","99",2016.0,"99"
"LAO","101.9901968","20.27482773","418","Lao People's Democratic Republic","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","72","77","78",2016.0,"78"
"","","","419","Latin America and the Caribbean","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","2.99945","10.72789","35.48784","60.30619","71.20318","73.69062","78.87612","82.23396","80.90851",2016.0,"80.90851"
"LSO","28.25362195","-29.58041814","426","Lesotho","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","29","93",2016.0,"93"
"LVA","26.42461876","56.64196636","428","Latvia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","76","55","83","83","82","82",2016.0,"82"
"LBR","-9.311879038","6.448381009","430","Liberia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","45","56","79",2016.0,"79"
"","","","432","Landlocked developing countries (LLDCs)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","2","8","23","31","53","60","70",2016.0,"70"
"LBY","18.0295985","27.04042819","434","Libya","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","39","71","96",2016.0,"96"
"BHS","-78.05111663","24.69546597","44","Bahamas","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","3","1","1","37","97","96","95","94",2016.0,"94"
"LTU","23.90517807","55.33680309","440","Lithuania","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","E","","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","","82",2016.0,"82"
"LUX","6.092656563","49.77679538","442","Luxembourg","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","86","86","86","86","95","95","95","95","95",2016.0,"95"
"MDG","46.6982339","-19.38514785","450","Madagascar","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","76","72","69","76",2016.0,"76"
"MWI","33.4884625","-13.40819859","454","Malawi","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","99","89","87","88","83",2016.0,"83"
"MLI","-3.522016039","17.35311254","466","Mali","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","56","68","71","73","53","70",2016.0,"70"
"MRT","-10.33187259","20.26089546","478","Mauritania","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","1","71","71","73",2016.0,"73"
"BHR","50.5490754","26.04407747","48","Bahrain","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","14","96","99","99","99","99","98","98","99",2016.0,"99"
"MUS","57.568022","-20.28581998","480","Mauritius","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","E","","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","","10",2016.0,"10"
"MEX","-102.5148166","23.93378032","484","Mexico","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","14","46","92","98","99","84","94","93","92",2016.0,"92"
"","","","485","Western Asia (exc. Armenia, Azerbaijan, Cyprus, Israel and Georgia)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","86","87","87","86","81","82","81","79","81",2016.0,"81"
"MDA","28.4650624","47.20236795","498","Republic of Moldova","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","1","28","71","77",2016.0,"77"
"","","","5","South America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","1","22","55","71","79","81","85","83",2016.0,"83"
"BGD","89.17660788","22.86961622","50","Bangladesh","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","48","97",2016.0,"97"
"MAR","-6.281942841","31.8440131","504","Morocco","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","1","23","72","80","90","95","98",2016.0,"98"
"MOZ","38.18479941","-14.27963886","508","Mozambique","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","45","73","80","80",2016.0,"80"
"ARM","44.93839317","40.29499741","51","Armenia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","44","94",2016.0,"94"
"OMN","57.87743482","21.98805614","512","Oman","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","96","99","99","99","99","98","98","99",2016.0,"99"
"","","","514","Developed regions (Europe, Cyprus, Israel, Northern America, Japan, Australia & New Zealand)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","37","41","52","55","56","57","58","66","71",2016.0,"71"
"","","","515","Developing regions","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","80","83","84","84","84","84","84","84","85",2016.0,"85"
"NAM","17.21907885","-22.13817068","516","Namibia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","81","81",2016.0,"81"
"","","","518","Eastern Asia (excluding Japan)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","97","99","99","99","99","99","99","99","99",2016.0,"99"
"BRB","-59.5346489","13.13648273","52","Barbados","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","75","78","81","84","87","90","97","96",2016.0,"96"
"NPL","83.94678863","28.25866332","524","Nepal","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","5","46",2016.0,"46"
"NLD","5.331480568","51.86728884","528","Netherlands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","96","96","96","96","96","95","94","94",2016.0,"94"
"","","","53","Australia and New Zealand","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","74.84975","90.29824","90.65351","91.17102","91.16912","91.33507","91.33242","93.00013","93.83517",2016.0,"93.83517"
"","","","54","Melanesia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","0","0","6","7","26","29",2016.0,"29"
"NZL","170.4755673","-43.98721568","554","New Zealand","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","87","89","92","92","93","93","93","93",2016.0,"93"
"NIC","-85.03060315","12.84210839","558","Nicaragua","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","61","98","98","98","98","98",2016.0,"98"
"BEL","4.660976456","50.64104975","56","Belgium","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","93","93","93","94","94",2016.0,"94"
"NER","9.400167877","17.42143036","562","Niger","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","13","49","64",2016.0,"64"
"NGA","8.097363256","9.585789025","566","Nigeria","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","13","26",2016.0,"26"
"","","","57","Micronesia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","9","30","30","32","49","55","71","68",2016.0,"68"
"NIU","-169.8601693","-19.05000475","570","Niue","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","99","99","99","99","99","99","99","99",2016.0,"99"
"NOR","11.47846389","61.34311134","578","Norway","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","86","91","91","92","93","93","91","93","94",2016.0,"94"
"FSM","158.225216","6.880670092","583","Micronesia (Federated States of)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","70","63","60","61","64","67","63",2016.0,"63"
"MHL","171.0839119","7.110213497","584","Marshall Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","49","24","35","46","38","29","75","51",2016.0,"51"
"PLW","134.5733878","7.502307591","585","Palau","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","7","18","45","61","82","93","93","95","98",2016.0,"98"
"PAK","68.80479684","29.36491634","586","Pakistan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","66","72","72","72",2016.0,"72"
"PAN","-81.26616623","8.450965746","591","Panama","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","48","55","62","68","75","82","83",2016.0,"83"
"PNG","145.8587761","-6.756057077","598","Papua New Guinea","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","20","20",2016.0,"20"
"PRY","-60.54854225","-21.70216237","600","Paraguay","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","82","90","88","92","99",2016.0,"99"
"PER","-71.82093277","-13.58939705","604","Peru","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","9","83","82","89","85","86","90","86",2016.0,"86"
"PHL","120.8601418","14.16591706","608","Philippines","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","35","17","36",2016.0,"36"
"","","","61","Polynesia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","0","0","0","0","0","0","0","0",2016.0,"0"
"GNB","-14.40182514","12.11760394","624","Guinea-Bissau","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","10","80",2016.0,"80"
"QAT","51.19152467","25.28355379","634","Qatar","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","99","97","98","92","99","94","95","97",2016.0,"97"
"RUS","99.01404926","61.61899849","643","Russian Federation","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","E","","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","","35",2016.0,"35"
"RWA","29.92310194","-1.999842114","646","Rwanda","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","97","97","98","98","98","98","98",2016.0,"98"
"SMR","12.46329038","43.93841766","674","San Marino","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","E","","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","","12",2016.0,"12"
"STP","6.609772265","0.241554875","678","Sao Tome and Principe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","97","95","96","96",2016.0,"96"
"BOL","-64.66224284","-16.71273412","68","Bolivia (Plurinational State of)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","56","96","97",2016.0,"97"
"SAU","44.54763347","24.12594211","682","Saudi Arabia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","98","98","98","98","98","98","98","98",2016.0,"98"
"SEN","-14.46636926","14.35920905","686","Senegal","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","81","89","93",2016.0,"93"
"SLE","-11.78306584","8.568604164","694","Sierra Leone","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","75","92","92","83","86","84",2016.0,"84"
"SGP","103.8107883","1.361009155","702","Singapore","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","17","22","40","52","60","69","75","78",2016.0,"78"
"SVK","19.48495604","48.70741446","703","Slovakia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","99","99","99","99","98","96","96","96",2016.0,"96"
"SVN","14.82209486","46.11958061","705","Slovenia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","49","50",2016.0,"50"
"ZAF","24.67184355","-29.99957544","710","South Africa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","10","58","62","70","69","72","77","69",2016.0,"69"
"ZWE","29.86909584","-19.00075492","716","Zimbabwe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","21","95","91","87","90",2016.0,"90"
"BWA","23.81380223","-22.18810073","72","Botswana","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","52","72","95","95","95",2016.0,"95"
"","","","722","Small island developing States (SIDS)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","0","1","1","3","5","8","13","17","23",2016.0,"23"
"","","","729","Sudan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","30","97","93","93",2016.0,"93"
"","","","738","Sub-Saharan Africa (inc. Sudan)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","70","73","72","72","72","72","74","73","74",2016.0,"74"
"","","","746","Northern Africa (exc. Sudan)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","97","97","97","96","95","97","95","95","95",2016.0,"95"
"SWZ","31.50149288","-26.56471011","748","Eswatini","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","67","90","90",2016.0,"90"
"SWE","14.3775338","60.60103109","752","Sweden","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","60","98","98","98","97","97","97","97","97",2016.0,"97"
"CHE","8.223158","46.96617097","756","Switzerland","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","13","25","37","50","62","75","80","81","81",2016.0,"81"
"BRA","-53.08432878","-10.77668561","76","Brazil","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","24","82","88","94","93","94","94",2016.0,"94"
"TGO","0.97835765","8.532096072","768","Togo","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","34","86","89",2016.0,"89"
"TTO","-61.29389504","10.41877263","780","Trinidad and Tobago","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","E","E","E","E","E","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","39","80","95","93","91",2016.0,"91"
"ARE","53.98279159","23.43322219","784","United Arab Emirates","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","94","95","96","98","99","99","99",2016.0,"99"
"TUR","35.42890329","38.9899684","792","Turkey","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","E","E","E","E","E","E","E","E","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","97","93","96","97","97","96","97","98",2016.0,"98"
"ALB","20.06660928","41.13897007","8","Albania","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","99","99","99","99","99","98",2016.0,"98"
"UGA","32.39100438","1.279557331","800","Uganda","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","50","66","78",2016.0,"78"
"GBR","-2.23830539","53.27691757","826","United Kingdom of Great Britain and Northern Ireland","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","89","90","92","93","93","93","92",2016.0,"92"
"TZA","34.80521182","-6.265332606","834","United Republic of Tanzania","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","E","E","E","E","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","80","93","95","96",2016.0,"96"
"USA","-99.13830311","39.5277871","840","United States of America","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","93","93","93","94","92","92","93","93","93",2016.0,"93"
"BFA","-1.742843829","12.27491081","854","Burkina Faso","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","91","91","91",2016.0,"91"
"URY","-56.01387025","-32.8002838","858","Uruguay","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","E","E","E","E","E","E","E","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","91","92","93","93","95","94","94",2016.0,"94"
"UZB","63.11944558","41.77560518","860","Uzbekistan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","E","","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","","99",2016.0,"99"
"VEN","-66.15642084","7.121324748","862","Venezuela (Bolivarian Republic of)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","24","7",2016.0,"7"
"YEM","45.22389143","15.22242099","887","Yemen","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","E","E","E","E","E","E","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","41","67","73","73","69","71",2016.0,"71"
"ZMB","27.850329","-14.59701056","894","Zambia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","E","E","E","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","77","81","90",2016.0,"90"
"","","","9","Oceania","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","E","E","E","E","E","E","E","E","E","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","43","53","53","54","54","56","57","65","67",2016.0,"67"
"SLB","160.1584117","-9.622391719","90","Solomon Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","E","E","","","","","","","","WHO/UNICEF coverage estimates 2016 revision, July 2017","WHO/UNICEF coverage estimates 2016 revision, July 2017","","","","","","","","","","","","","","","","","42","87",2016.0,"87"
"ATA","21.47585697","-80.40897662","10","Antarctica","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ASM","-170.7187269","-14.30587306","16","American Samoa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ATG","-61.7999755","17.07761471","28","Antigua and Barbuda","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"AUT","14.14172472","47.58704857","40","Austria","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"BMU","-64.78155012","32.27881922","60","Bermuda","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"BTN","90.45098484","27.39598568","64","Bhutan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"BIH","17.78584332","44.16845548","70","Bosnia and Herzegovina","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"BVT","3.410732868","-54.43295905","74","Bouvet Island","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"BLZ","-88.70199554","17.19965901","84","Belize","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"IOT","72.38715553","-7.299281071","86","British Indian Ocean Territory","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"VGB","-64.63294223","18.42256578","92","British Virgin Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"BRN","114.6288563","4.49736984","96","Brunei Darussalam","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"BLR","28.04940161","53.54193075","112","Belarus","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"CPV","-23.63544151","15.07791834","132","Cabo Verde","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"CYM","-81.16740559","19.32266656","136","Cayman Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"LKA","80.70489654","7.614693343","144","Sri Lanka","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TCD","18.66618401","15.36279341","148","Chad","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"CHN","104.1403375","32.30955217","156","China","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"CXR","105.6426067","-10.4882473","162","Christmas Island","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"CCK","96.82633757","-12.18600682","166","Cocos (Keeling) Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"COM","43.34234565","-11.66121732","174","Comoros","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MYT","45.14015057","-12.82217691","175","Mayotte","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"COK","-159.7711391","-21.22696458","184","Cook Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"HRV","17.95874553","45.45172212","191","Croatia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"CUB","-79.54460144","22.10030366","192","Cuba","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"CZE","15.33151382","49.73913871","203","Czechia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"DMA","-61.3493756","15.43391378","212","Dominica","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GNQ","10.46535826","1.565792376","226","Equatorial Guinea","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"EST","25.84093481","58.68487172","233","Estonia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"FRO","-7.122044325","62.21228119","234","Faroe Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"FLK","-58.75246778","-51.74562601","238","Falkland Islands (Malvinas)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SGS","-36.90662765","-54.20736749","239","South Georgia and the South Sandwich Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ALA","19.80945969","60.1544901","248","land Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GUF","-53.23619089","3.922673437","254","French Guiana","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"PYF","-149.4052367","-17.67709294","258","French Polynesia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ATF","69.64849091","-49.6068576","260","French Southern Territories","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GAB","11.78727747","-0.60687619","266","Gabon","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GIB","-5.347561686","36.13895036","292","Gibraltar","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GRL","-41.39371316","74.75625681","304","Greenland","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GRD","-61.68248568","12.11238395","308","Grenada","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GLP","-61.64762115","16.14416917","312","Guadeloupe","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GUM","144.7029305","13.35485404","316","Guam","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GIN","-11.28173419","11.00210343","324","Guinea","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"HTI","-72.33640958","18.40426539","332","Haiti","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"HMD","73.52633626","-53.09106147","334","Heard Island and McDonald Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"VAT","12.45315803","41.90343751","336","Holy See","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"HKG","114.0266445","22.41749934","344","China, Hong Kong Special Administrative Region","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"IND","79.3608464","22.34642074","356","India","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"IDN","113.9174","-0.994582204","360","Indonesia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"IRN","54.19766348","32.74370885","364","Iran (Islamic Republic of)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"IRQ","43.76606267","33.05013795","368","Iraq","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"JAM","-77.31068409","18.15616857","388","Jamaica","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"JOR","37.13024774","30.65365973","400","Jordan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"PRK","127.1803633","40.1462645","408","Democratic People's Republic of Korea","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"KGZ","74.52324839","41.46204516","417","Kyrgyzstan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"LBN","35.89391711","33.92152458","422","Lebanon","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"LIE","9.552985019","47.14167005","438","Liechtenstein","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MAC","113.5665388","22.1237259","446","China, Macao Special Administrative Region","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MYS","116.8346314","5.452415309","458","Malaysia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MDV","73.09672546","-0.614385021","462","Maldives","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MLT","14.44617519","35.89194275","470","Malta","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MTQ","-60.91544135","14.56086108","474","Martinique","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MCO","7.424214814","43.73532918","492","Monaco","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MNG","103.0728057","46.83892054","496","Mongolia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MNE","19.25214024","42.78717043","499","Montenegro","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MSR","-62.19261223","16.73558313","500","Montserrat","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"NRU","166.92313","-0.528742623","520","Nauru","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ANT","-68.30676179","12.22720635","530","Netherlands Antilles","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"CUW","-68.95033464","12.15058042","531","Curaao","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ABW","-69.97050586","12.50878756","533","Aruba","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SXM","-63.06198692","18.03926508","534","Sint Maarten (Dutch part)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"NCL","165.5067368","-21.41742531","540","New Caledonia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"VUT","167.0679779","-15.34445547","548","Vanuatu","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"NFK","167.9515548","-29.03230018","574","Norfolk Island","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MNP","145.7582114","15.19099517","580","Northern Mariana Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"UMI","-162.4343752","5.874443968","581","US Minor Outlying Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"FSM","158.225216","6.880670092","583","Micronesia, Federated States of","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"PCN","-128.3225873","-24.37538456","612","Pitcairn","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"POL","19.40660158","52.1226733","616","Poland","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"PRT","-7.961599811","39.68509315","620","Portugal","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TLS","125.9451052","-8.797497247","626","Timor-Leste","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"PRI","-66.47591017","18.22753799","630","Puerto Rico","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"REU","55.53171398","-21.13183266","638","Runion","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ROU","24.98481009","45.83893563","642","Romania","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"BLM","-62.83173536","17.89513362","652","Saint Barthlemy","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SHN","-5.705752501","-15.96503946","654","Saint Helena","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"KNA","-62.76628613","17.33994219","659","Saint Kitts and Nevis","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"AIA","-63.05651612","18.21525315","660","Anguilla","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"LCA","-60.96529553","13.89405601","662","Saint Lucia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MAF","-63.04505461","18.0882685","663","Saint Martin (French Part)","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SPM","-56.33682442","46.85812735","666","Saint Pierre and Miquelon","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"VCT","-61.19024321","13.24627968","670","Saint Vincent and the Grenadines","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SRB","20.805876","44.03145697","688","Serbia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SYC","55.46561591","-4.678053059","690","Seychelles","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"VNM","105.802499","10.09643079","704","Viet Nam","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SOM","46.20367477","4.406485729","706","Somalia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ESP","-3.554078296","40.39211472","724","Spain","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SSD","30.32618773","7.290839152","728","South Sudan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"ESH","-13.13515523","24.66265342","732","Western Sahara","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SDN","29.95650159","16.02643066","736","Sudan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SUR","-55.90626394","4.132603197","740","Suriname","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SJM","13.38071013","78.82894131","744","Svalbard and Jan Mayen Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"SYR","38.50466565","35.01676176","760","Syrian Arab Republic","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TJK","69.294998","38.43069666","762","Tajikistan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"THA","101.0202951","15.13089239","764","Thailand","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TKL","-171.8154473","-9.214545558","772","Tokelau","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TON","-175.1959991","-21.19511329","776","Tonga","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TUN","9.572737411","34.11439971","788","Tunisia","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TKM","58.9787665","40.0912346","795","Turkmenistan","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TCA","-71.745121","21.80780585","796","Turks and Caicos Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TUV","178.6679611","-7.460048071","798","Tuvalu","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"UKR","31.40270802","49.00735945","804","Ukraine","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"MKD","21.7007909","41.60048068","807","Macedonia, Republic of","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"EGY","29.77468534","26.57438204","818","Egypt","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GBR","-2.23830539","53.27691757","826","United Kingdom","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"GGY","-2.200712402","49.71561166","831","Guernsey","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"JEY","-2.136773508","49.22353354","832","Jersey","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"IMN","-4.538190305","54.22880901","833","Isle of Man","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"TZA","34.80521182","-6.265332606","834","Tanzania, United Republic of","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"VIR","-64.76960113","17.73297693","850","United States Virgin Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"WLF","-176.2034788","-13.28471201","876","Wallis and Futuna Islands","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
"WSM","-172.4430749","-13.61541469","882","Samoa","3","Ensure healthy lives and promote well-being for all at all ages","3.b","Support the research and development of vaccines and medicines for the communicable and non-communicable diseases that primarily affect developing countries, provide access to affordable essential medicines and vaccines, in accordance with the Doha Declaration on the TRIPS Agreement and Public Health, which affirms the right of developing countries to use to the full the provisions in the Agreement on Trade-Related Aspects of Intellectual Property Rights regarding flexibilities to protect public health, and, in particular, provide access to medicines for all","3.b.1","Proportion of the target population covered by all vaccines included in their national programme","2","SH_ACS_PCV3","Proportion of the target population with access to pneumococcal conjugate 3rd dose (PCV3) (%)","2019.Q1.G.01","G","Global","PERCENT","Percentage","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","","",""
